Hydrochloric Acid → HCID 178434251, 화합물

반응식

[NH2:1][C:2]1[C:7]([N:8]2[CH2:13][CH2:12][N:11](C(OC(C)(C)C)=O)[C@@H:10]([CH2:21][C:22]3[CH:27]=[CH:26][CH:25]=[CH:24][CH:23]=3)[CH2:9]2)=[N:6][C:5]([C:28]2[CH:29]=[C:30]3[C:34](=[CH:35][CH:36]=2)[NH:33][N:32]=[C:31]3[CH3:37])=[CH:4][N:3]=1.Cl>ClCCl.O1CCOCC1>[NH2:1][C:2]1[C:7]([N:8]2[CH2:13][CH2:12][NH:11][C@@H:10]([CH2:21][C:22]3[CH:23]=[CH:24][CH:25]=[CH:26][CH:27]=3)[CH2:9]2)=[N:6][C:5]([C:28]2[CH:29]=[C:30]3[C:34](=[CH:35][CH:36]=2)[NH:33][N:32]=[C:31]3[CH3:37])=[CH:4][N:3]=1

참가 물질

실험 절차

To a solution of 2-amino-3-[(S)-4-Boc-3-benzylpiperazinyl]-5-(3-methyl-1H-indazol-5-yl)pyrazine 109 (20 mg, 0.04 mmol) in dichloromethane (2 mL) was added a 4 M solution of HCl in dioxane (2 mL). The reaction mixture was stirred at room temperature for 1 hour. The organic solvent was evaporated under reduced pressure. The crude product was purified by RP-HPLC to yield the desired 2-amino-3-[(S)-3-benzylpiperazinyl]-5-(3-methyl-1H-indazol-5-yl)pyrazine 110 (12 mg, 0.03 mmol).